Study of Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of of HZBio1 in Healthy Subjects

NCT ID: NCT04765995

Last Updated: 2025-05-13

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 40 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2021-03-01
• Study Completion Date: 2022-01-14

Brief Summary

This randomized study will evaluate the safety, tolerability ,pharmacokinetics, pharmacodynamics and Immunogenicity of single ascending intramuscularly administered doses of HZBio1 in healthy volunteers.

Conditions

Healthy Participants

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

HZBio1 0.96mg/kg

Participants will receive intramuscularly 0.96 milligram per kilogram (mg/kg) of HZBio1.

Group Type: EXPERIMENTAL

HZBio1 0.96mg / kg

Intervention Type: DRUG

HZBio1 will be administered intramuscularly in single ascending doses with starting of 0.96 mg/kg and subsequent doses of 3.0 mg/kg, 6.0 mg/kg ,9.0 mg/kg,and 12mg/kg, respectively.

Placebo

Intervention Type: DRUG

Matching placebo will be administered intramuscularly.

HZBio1 3mg/kg

Participants will receive intramuscularly 3 milligram per kilogram (mg/kg) of HZBio1.

Group Type: EXPERIMENTAL

HZBio1 3mg / kg

Intervention Type: DRUG

HZBio1 will be administered intramuscularly in single ascending doses with starting of 0.96 mg/kg and subsequent doses of 3.0 mg/kg, 6.0 mg/kg ,9.0 mg/kg,and 12mg/kg, respectively.

Placebo

Intervention Type: DRUG

Matching placebo will be administered intramuscularly.

HZBio1 6mg/kg

Participants will receive intramuscularly 6 milligram per kilogram (mg/kg) of HZBio1.

Group Type: EXPERIMENTAL

HZBio1 6mg / kg

Intervention Type: DRUG

HZBio1 will be administered intramuscularly in single ascending doses with starting of 0.96 mg/kg and subsequent doses of 3.0 mg/kg, 6.0 mg/kg ,9.0 mg/kg,and 12mg/kg, respectively.

Placebo

Intervention Type: DRUG

Matching placebo will be administered intramuscularly.

HZBio1 9mg/kg

Participants will receive intramuscularly 9milligram per kilogram (mg/kg) of HZBio1.

Group Type: EXPERIMENTAL

HZBio1 9mg / kg

Intervention Type: DRUG

HZBio1 will be administered intramuscularly in single ascending doses with starting of 0.96 mg/kg and subsequent doses of 3.0 mg/kg, 6.0 mg/kg ,9.0 mg/kg,and 12mg/kg, respectively.

Placebo

Intervention Type: DRUG

Matching placebo will be administered intramuscularly.

HZBio1 12mg/kg

Participants will receive intramuscularly 12 milligram per kilogram (mg/kg) of HZBio1.

Group Type: EXPERIMENTAL

HZBio1 12mg / kg

Intervention Type: DRUG

HZBio1 will be administered intramuscularly in single ascending doses with starting of 0.96 mg/kg and subsequent doses of 3.0 mg/kg, 6.0 mg/kg ,9.0 mg/kg,and 12mg/kg, respectively.

Placebo

Intervention Type: DRUG

Matching placebo will be administered intramuscularly.

Interventions

HZBio1 0.96mg / kg

HZBio1 will be administered intramuscularly in single ascending doses with starting of 0.96 mg/kg and subsequent doses of 3.0 mg/kg, 6.0 mg/kg ,9.0 mg/kg,and 12mg/kg, respectively.

Intervention Type: DRUG

HZBio1 3mg / kg

HZBio1 will be administered intramuscularly in single ascending doses with starting of 0.96 mg/kg and subsequent doses of 3.0 mg/kg, 6.0 mg/kg ,9.0 mg/kg,and 12mg/kg, respectively.

Intervention Type: DRUG

HZBio1 6mg / kg

HZBio1 will be administered intramuscularly in single ascending doses with starting of 0.96 mg/kg and subsequent doses of 3.0 mg/kg, 6.0 mg/kg ,9.0 mg/kg,and 12mg/kg, respectively.

Intervention Type: DRUG

HZBio1 9mg / kg

HZBio1 will be administered intramuscularly in single ascending doses with starting of 0.96 mg/kg and subsequent doses of 3.0 mg/kg, 6.0 mg/kg ,9.0 mg/kg,and 12mg/kg, respectively.

Intervention Type: DRUG

HZBio1 12mg / kg

HZBio1 will be administered intramuscularly in single ascending doses with starting of 0.96 mg/kg and subsequent doses of 3.0 mg/kg, 6.0 mg/kg ,9.0 mg/kg,and 12mg/kg, respectively.

Intervention Type: DRUG

Placebo

Matching placebo will be administered intramuscularly.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Fully informed and signed informed consent form;

2. Healthy subjects, male and female;

3. At the time of signing the informed consent, they were over 18-45 years old (including 18 and 45 years old) and weighed more than 50 kg,

Body mass index ranged from 19 to 26 (including 19 and 26) [body mass index (BMI) = body weight (kg) / height 2 (M2)];

4. The results of serum pregnancy test in women of childbearing age were negative;

5. The subjects agreed to use effective contraception or abstinence during the study period and within 6 months after the end of the study;

6. Be able to understand and comply with the clinical protocol requirements, and it is expected to complete the whole trial process.

Exclusion Criteria

1. History of hypertension or abnormal blood pressure at screening / baseline (SBP > 140 mmHg and / or DBP > 90 mmHg confirmed twice a day)

2. According to the researcher's judgment (clinical urine routine examination, proteinuria 2 + and above), proteinuria or proteinuria history with clinical significance.

3. Any previous VEGF and VEGFR antibody or protein therapy within one year.

4. No biological products or live virus vaccine shall be used for treatment for 3 months before the first administration of the study drug, or any monoclonal antibody shall be used for 12 months.

5. History or evidence of hereditary bleeding, coagulopathy, or thrombosis.

6. History of gastrointestinal perforation or fistula.

7. Severe, unhealed wounds, active ulcers, or untreated fractures, or were randomly assigned or expected to require major surgery during the course of the study or within 2 months after the last administration of the study drug.

8. RX or OTC drugs or nutritional supplements were used within 5 half lives before the first administration of the study drug or within 2 weeks (depending on the longer period). Herbal supplements need to be discontinued 28 days before the first administration of the study drug.

9. HBsAg, HCV antibody, HIV antibody and syphilis were positive

10. Known allergy to bevacizumab or any excipient

11. Known allergic diseases or allergic constitution

12. There was a history of unpaid blood donation within 3 months before taking the study drug for the first time

13. Use any other study drug for treatment or participate in other clinical trials within 3 months before screening

14. There was a history of alcohol or drug abuse within 12 months before screening; subjects were not able to control within 72 hours before and throughout the study

15. History of mental illness

16. During the study, the partner was expected to be pregnant.

17. During the study period, it did not conform to the clinical study protocol.

18. Other conditions not suitable for this study were considered by the researchers

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 50 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Peking Union Medical College Hospital

OTHER

Sponsor Role: collaborator

Hangzhou Grand Biologic Pharmaceutical, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Hongzhong Liu

Role: PRINCIPAL_INVESTIGATOR

Peking Union Medical College Hospital

Xin Zheng

Role: PRINCIPAL_INVESTIGATOR

Peking Union Medical College Hospital

Locations

Peking Union Medical College Hospital

Beijing, , China

Countries

China

Other Identifiers

YDHY（HZBio1）-001（I）

Identifier Type: -

Identifier Source: org_study_id